|
1
|
Westlind A, Malmebo S, Johansson I, Otter
C, Andersson TB, Ingelman-Sundberg M and Oscarson M: Cloning and
tissue distribution of a novel human cytochrome p450 of the CYP3A
subfamily, CYP3A43. Biochem Biophys Res Commun. 281:1349–1355.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sevrioukova IF and Poulos TL:
Understanding the mechanism of cytochrome P450 3A4: recent advances
and remaining problems. Dalton transactions. 42:3116–3126. 2013.
View Article : Google Scholar :
|
|
3
|
de Wildt SN, Kearns GL, Leeder JS and van
den Anker JN: Cytochrome P450 3A: Ontogeny and drug disposition.
Clin Pharmacokinet. 37:485–505. 1999. View Article : Google Scholar
|
|
4
|
Lamba JK, Lin YS, Schuetz EG and Thummel
KE: Genetic contribution to variable human CYP3A-mediated
metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Urquhart BL, Tirona RG and Kim RB: Nuclear
receptors and the regulation of drug-metabolizing enzymes and drug
transporters: Implications for interindividual variability in
response to drugs. J Clin Pharmacol. 47:566–578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keshava C, McCanlies EC and Weston A:
CYP3A4 polymorphisms-potential risk factors for breast and prostate
cancer: A HuGE review. Am J Epidemiol. 160:825–841. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wojnowski L and Kamdem LK: Clinical
implications of CYP3A polymorphisms. Expert Opin Drug Metab
Toxicol. 2:171–182. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perera MA: The missing linkage: What
pharmacogenetic associations are left to find in CYP3A? Expert Opin
Drug Metab Toxicol. 6:17–28. 2010. View Article : Google Scholar
|
|
9
|
Klein K and Zanger UM: Pharmacogenomics of
Cytochrome P450 3A4: Recent progress toward the ῾Missing
Heritability᾿ problem. Front Genet. 4:122013. View Article : Google Scholar
|
|
10
|
Kitazono M, Sumizawa T, Takebayashi Y,
Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and
Akiyama S: Multidrug resistance and the lung resistance-related
protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst.
91:1647–1653. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Willson TM and Kliewer SA: PXR, CAR and
drug metabolism. Nat Rev Drug Discov. 1:259–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Timsit YE and Negishi M: CAR and PXR: The
xenobiotic-sensing receptors. Steroids. 72:231–246. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klein K, Thomas M, Winter S, Nussler AK,
Niemi M, Schwab M and Zanger UM: PPARA: A novel genetic determinant
of CYP3A4 in vitro and in vivo. Clin Pharmacol Ther. 91:1044–1052.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oda Y, Nakajima M, Tsuneyama K, Takamiya
M, Aoki Y, Fukami T and Yokoi T: Retinoid X receptor α in human
liver is regulated by miR-34a. Biochem Pharmacol. 90:179–187. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang J, Hao C, Yang D, Shi D, Song X, Luan
X, Hu G and Yan B: Pregnane X receptor is required for
interleukin-6-mediated down-regulation of cytochrome P450 3A4 in
human hepatocytes. Toxicol Lett. 197:219–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watanabe K, Sakurai K, Tsuchiya Y, Yamazoe
Y and Yoshinari K: Dual roles of nuclear receptor liver X receptor
α (LXRα) in the CYP3A4 expression in human hepatocytes as a
positive and negative regulator. Biochem Pharmacol. 86:428–436.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goodwin B, Hodgson E, D'Costa DJ,
Robertson GR and Liddle C: Transcriptional regulation of the human
CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol.
62:359–365. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang K, Chen S, Xie W and Wan YJ:
Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated
pathway. Biochem Pharmacol. 75:2204–2213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thirumaran RK, Lamba JK, Kim RB, Urquhart
BL, Gregor JC, Chande N, Fan Y, Qi A, Cheng C, Thummel KE, et al:
Intestinal CYP3A4 and midazolam disposition in vivo associate with
VDR polymorphisms and show seasonal variation. Biochem Pharmacol.
84:104–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones SA, Moore LB, Shenk JL, Wisely GB,
Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH,
Willson TM, et al: The pregnane X receptor: A promiscuous
xenobiotic receptor that has diverged during evolution. Mol
Endocrinol. 14:27–39. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aitken AE and Morgan ET: Gene-specific
effects of inflammatory cytokines on cytochrome p450 2c, 2b6 and
3a4 mrna levels in human hepatocytes. Drug Metab Dispos.
35:1687–1693. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dickmann LJ, Patel SK, Wienkers LC and
Slatter JG: Effects of Interleukin 1β (IL-1β) and IL-1β/interleukin
6 (IL-6) combinations on drug metabolizing enzymes in human
hepatocyte culture. Curr Drug Metab. 13:930–937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wolbold R, Klein K, Burk O, Nüssler AK,
Neuhaus P, Eichelbaum M, Schwab M and Zanger UM: Sex is a major
determinant of CYP3A4 expression in human liver. Hepatology.
38:978–988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vilalta A, Kickhoefer VA, Rome LH and
Johnson DL: The rat vault RNA gene contains a unique RNA polymerase
III promoter composed of both external and internal elements that
function synergistically. J Biol Chem. 269:29752–29759.
1994.PubMed/NCBI
|
|
25
|
Kickhoefer VA, Rajavel KS, Scheffer GL,
Dalton WS, Scheper RJ and Rome LH: Vaults are up-regulated in
multidrug-resistant cancer cell lines. J Biol Chem. 273:8971–8974.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Zon A, Mossink MH, Schoester M,
Scheffer GL, Scheper RJ, Sonneveld P and Wiemer EA: Multiple human
vault RNAs: expression and association with the vault complex. J
Biol Chem. 276:37715–37721. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kitazono M, Okumura H, Ikeda R, Sumizawa
T, Furukawa T, Nagayama S, Seto K, Aikou T and Akiyama S: Reversal
of LRP-associated drug resistance in colon carcinoma SW-620 cells.
Int J Cancer. 91:126–131. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Patel J and Mitra AK: Strategies to
overcome simultaneous P-glycoprotein mediated efflux and CYP3A4
mediated metabolism of drugs. Pharmacogenomics. 2:401–415. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Siva AC, Raval-Fernandes S, Stephen AG,
LaFemina MJ, Scheper RJ, Kickhoefer VA and Rome LH: Up-regulation
of vaults may be necessary but not sufficient for multidrug
resistance. Int J Cancer. 92:195–202. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Persson H, Kvist A, Vallon-Christersson J,
Medstrand P, Borg A and Rovira C: The non-coding RNA of the
multidrug resistance-linked vault particle encodes multiple
regulatory small RNAs. Nat Cell Biol. 11:1268–1271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Michaelis L and Menten ML: Die kinetik der
invertinwirkung. Biochem Z. 49:333–369. 1913.
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
